Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries.
about
Oxidative stress modulation in hepatitis C virus infected cellsHepatitis C: Treatment of difficult to treat patientsReRouting biomedical innovation: observations from a mapping of the alternative research and development (R&D) landscapeComparative molecular dynamics simulation of Hepatitis C Virus NS3/4A protease (Genotypes 1b, 3a and 4b) predicts conformational instability of the catalytic triad in drug resistant strainsPrices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic AnalysisAnalysis of minimum target prices for production of entecavir to treat hepatitis B in high- and low-income countriesExploration of acetanilide derivatives of 1-(ω-phenoxyalkyl)uracils as novel inhibitors of Hepatitis C Virus replicationThe Brazilian comprehensive response to hepatitis C: from strategic thinking to access to interferon-free therapyThe impact of HCV therapy in a high HIV-HCV prevalence population: A modeling study on people who inject drugs in Ho Chi Minh City, VietnamData exclusivity exceptions and compulsory licensing to promote generic medicines in the European Union: A proposal for greater coherence in European pharmaceutical legislation.Compulsory Licenses for Cancer Drugs: Does Circumventing Patent Rights Improve Access to Oncology Medications?Valuing cure: bridging cost-effectiveness and coverage decisions for hepatitis C therapy.Future of therapy for Hepatitis C in India: A Matter of Accessibility and Affordability?Are there national strategies, plans and guidelines for the treatment of hepatitis C in people who inject drugs? A survey of 33 European countries.Minimum target prices for production of direct-acting antivirals and associated diagnostics to combat hepatitis C virus.Highly divergent hepaciviruses from African cattle.Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis CCould international compulsory licensing reconcile tiered pricing of pharmaceuticals with the right to health?Hepatitis C virus: Is it time to say goodbye yet? Perspectives and challenges for the next decade.Challenges in managing HIV in people who use drugsVirological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort studyCost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United StatesManagement of telaprevir-based triple therapy for hepatitis C virus recurrence post liver transplant.Burden of substance use disorders, mental illness, and correlates of infectious diseases among soon-to-be released prisoners in Azerbaijan.Mathematical Modeling of Hepatitis C Prevalence Reduction with Antiviral Treatment Scale-Up in Persons Who Inject Drugs in Metropolitan ChicagoThe Mechanism of Interferon Refractoriness During Hepatitis C Virus Infection and Its Reversal with a Peroxisome Proliferator-Activated Receptor α AgonistBurden of hepatitis C virus disease and access to hepatitis C virus services in people who inject drugs in India: a cross-sectional study.Interferon-λ polymorphisms and response to pegylated interferon in Iranian hepatitis C patientsMolecular characterization of Hepatitis C virus 3a in PeshawarAll-oral interferon-free treatments: The end of hepatitis C virus story, the dream and the realityAccess to hepatitis C medicines.HCV co-infection and markers of liver injury and fibrosis among HIV-positive childbearing women in Ukraine: results from a cohort study.Trends in medicines procurement by the Brazilian federal government from 2006 to 2013.Target prices for mass production of tyrosine kinase inhibitors for global cancer treatment.Prevention of Hepatitis C by Screening and Treatment in U.S. Prisons.Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the FutureHepatitis C Virus: A Review of Treatment Guidelines, Cost-effectiveness, and Access to Therapy.Estimated generic prices of cancer medicines deemed cost-ineffective in England: a cost estimation analysis.Improved Survival Among all Interferon-α-Treated Patients in HCV-002, a Veterans Affairs Hepatitis C Cohort of 2211 Patients, Despite Increased Cirrhosis Among NonrespondersDaclatasvir for the treatment of hepatitis C virus infection.
P2860
Q26774003-C5E76B00-C2F5-4CCB-B5B4-BB61596FBC70Q26798465-118B5952-EA79-4029-8053-3CB557AC3832Q26970770-483B67A4-8FCA-486A-A378-83E25A92718DQ28541762-0A9EFA83-D68B-4776-B005-02F557D7F3DAQ28552507-F55202CA-BC42-446B-BB93-9D8DBD9CD782Q28830093-0F4F4092-AF4E-42C4-AF7A-9981E37DCAC7Q28830384-F0210061-F523-4F0C-BE3F-8708D231EFD9Q30061914-AA8FFCC5-8EC8-4EB3-A813-68E113E568B8Q33663998-5E2ED184-26D0-4A1A-B32B-A7680A0CA991Q33851099-6E05F892-59B6-458B-AAAC-CB1B4DDE83D9Q33859745-C17505D2-6019-414B-A72D-F0A34BEDE915Q33894256-731BEE71-8B68-489B-988F-5AD7045E5670Q33978118-953AD67C-7DE6-48B5-BCFE-F7D84FA3C580Q34260584-1C1A8E41-41FC-44A8-B152-A49A8D49490AQ34452419-9626ECB3-8964-46A7-9DCE-938CCEC9BDD1Q34467794-94EE7AEF-FAB2-43BF-ACA9-C43A62C8646DQ34536041-E9A909A3-BF42-4EBF-B2D3-8E6CAABD1F26Q34787572-DB78C567-67EB-40E5-A2BF-172571F6EEB8Q35501190-A5F56486-E7AF-4F69-9413-FAA3DF63AE13Q35538674-D25DE077-298B-4F0C-8372-3A7594FA8AECQ35592257-5C64276E-895D-4CDF-93A0-0BFEAE11F0F3Q35619161-9655AC10-46AE-4146-A67D-012DFEC07C9FQ35626794-5BBC9C0A-C089-4028-B175-FF76CFFDFEE9Q35661041-32408BDC-0AED-43C0-BDD3-B6D926930359Q35752296-B7A02042-1C47-4C4C-A5FD-0005666273C1Q35814700-B34A8ED4-D2DA-42AC-8EAF-5765016C5CF3Q35854698-5FAE2686-1196-4D2C-B85A-739F4753D6C3Q35925546-24D13A4A-9ADE-4D56-8D63-8EB754EB75C9Q35992896-9A137E59-EC9D-40B2-A63D-34129349F1CCQ36138623-F5BE1810-ACF8-4161-A3FC-D306E23507C6Q36211833-BDDEE2BF-B82A-4451-86E4-032D9729571FQ36220953-20A1A1EE-2F24-4763-BD4B-A39F786D3733Q36339862-E63F58A9-686F-4EA5-9151-ECF45C3B89D0Q36527174-CF425F18-0EA4-4204-9EFB-838D16CFB3CEQ36862066-D35F2398-7351-449D-837F-5728EE3783CFQ37135584-3B5607BF-51F9-4AC8-8D7A-4A00CF02A61AQ37578288-651A8457-36FF-47D5-A37C-5679DEA6D3E9Q37598156-1A238350-5C8E-44BF-A3FF-846C0FD2D067Q37641036-8D8F94AF-1220-4FC7-8050-AB090E6138B5Q38216586-A25A77E7-66CA-40DD-82BF-73C4C5E16348
P2860
Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Minimum costs for producing he ...... grams in developing countries.
@ast
Minimum costs for producing he ...... grams in developing countries.
@en
Minimum costs for producing he ...... grams in developing countries.
@nl
type
label
Minimum costs for producing he ...... grams in developing countries.
@ast
Minimum costs for producing he ...... grams in developing countries.
@en
Minimum costs for producing he ...... grams in developing countries.
@nl
prefLabel
Minimum costs for producing he ...... grams in developing countries.
@ast
Minimum costs for producing he ...... grams in developing countries.
@en
Minimum costs for producing he ...... grams in developing countries.
@nl
P2093
P2860
P356
P1476
Minimum costs for producing he ...... ograms in developing countries
@en
P2093
Andrew Hill
Joe Fortunak
Nathan Ford
P2860
P304
P356
10.1093/CID/CIU012
P407
P577
2014-01-06T00:00:00Z